



ALLOCATION OF FREE SHARES

Longjumeau, May 24, 2016

Exercising the authorization granted by the Shareholders' Meeting of April 21, 2016, and in keeping with the profit-sharing policy implemented previously, the meeting of the PCAS Board of Directors of May 11, 2016 decided to complete its allocation of free shares in favor of new beneficiaries.

The new allocations represent 156,204 shares that can be acquired until May 2019, with a retention period of one year.

To avoid further dilution of the capital, the decision was also made to allocate these shares, as well as those in previous plans that have not yet been issued, i.e. a total of 530,000 shares, for about 100 beneficiaries, by drawing from the treasury stock (1,480,000 shares), since the shares included in these allocations are held in a dedicated account until they are acquired by the beneficiaries.

About PCAS (Euronext Paris: BCP, eligible for the PEA-PME plan)

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers of a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. PCAS generated net sales of €179.1 million in 2015 and employs close to 900 people in six countries.

To find out more about PCAS, visit: www.pcas.com



PCAS

NewCap

Vincent Touraille / Eric Moissenot

Emmanuel Huynh

PCAS

NewCap

Financial communication and Investor Relations

Tel.: +33 1 69 79 61 32
www.pcas.com

Tel.: +33 1 44 71 94 94
pcas@newcap.eu